Europe

The government alleged Actelion provided money to a nonprofit to cover copay costs for Medicare drugs, a violation of the False Claims Act.

AstraZeneca and its MedImmune division announced results from its Phase III EAGLE clinical trial. Imfinzi, in combination with tremelimumab, an anti-CTLA4 antibody, compared to standard-of-care (SoC) chemotherapy, failed to meet its primary endpoints in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed after platinum-based chemotherapy, regardless of the PD-L1 status of their cancer.

Favorable safety and statistically significant efficacy demonstrated in a completed randomized, double-blind, placebo-controlled induction clinical trial based on clinical and endoscopic endpoints

Elafibranor successfully meets primary endpoint with high statistical significance of p<0.001

Analyst Jason McCarthy, PhD of Maxim Group updated coverage on Soligenix, Inc. on December 6, 2018. For more information, please visit www.maximgrp.com.

Resulting new tests will help researchers investigate links between gut microbiota and diabetes and obesity

Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS)

Dermavant Sciences today announced that the company will present new data on cerdulatinib during the 3rd Annual Inflammatory Skin Disease Summit (ISDS) taking place Dec. 12-15, 2018, in Vienna, Austria.

Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD

INTEGRA’s VIAFLO 96 electronic multi-channel pipetting system is helping biotechnology company HCS Pharma to improve the reproducibility of high content screening using its patented BIOMIMESYS® 3D cell culture technology.